Ultragenyx Pharmaceutical (NASDAQ:RARE) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research report sent to investors on Wednesday,Benzinga reports. Cantor Fitzgerald currently has a $118.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical’s FY2025 earnings at ($4.44) EPS.

RARE has been the subject of several other reports. Royal Bank of Canada reiterated an “outperform” rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. HC Wainwright reaffirmed a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. TD Cowen increased their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. Finally, Wedbush reissued a “neutral” rating and set a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Trading Down 1.8 %

Shares of Ultragenyx Pharmaceutical stock opened at $44.05 on Wednesday. The company’s 50-day moving average price is $44.56 and its 200-day moving average price is $49.57. Ultragenyx Pharmaceutical has a 12-month low of $37.02 and a 12-month high of $60.37. The company has a market cap of $4.07 billion, a price-to-earnings ratio of -6.81 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. The firm had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business’s quarterly revenue was up 42.3% compared to the same quarter last year. During the same period last year, the firm earned ($2.23) EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical will post -6.14 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Emil D. Kakkis sold 8,273 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the completion of the transaction, the chief executive officer now directly owns 2,195,712 shares in the company, valued at $109,785,600. This trade represents a 0.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC grew its stake in shares of Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after buying an additional 294 shares during the last quarter. Motley Fool Asset Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 0.3% in the third quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company’s stock worth $8,005,000 after acquiring an additional 360 shares during the last quarter. KBC Group NV increased its holdings in shares of Ultragenyx Pharmaceutical by 24.5% during the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 506 shares in the last quarter. M&T Bank Corp raised its position in shares of Ultragenyx Pharmaceutical by 8.1% in the 3rd quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company’s stock worth $388,000 after purchasing an additional 525 shares during the last quarter. Finally, Amalgamated Bank boosted its stake in Ultragenyx Pharmaceutical by 13.4% in the 2nd quarter. Amalgamated Bank now owns 5,896 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 696 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.